Table 5.
Baseline Characteristics for Age‐Matched Subgroup Analysis
| Nonsurvivors (n=7) | Survivors (n=14) | P Value | |
|---|---|---|---|
| Median (IQR) | Median (IQR) | ||
| Age at clinic entry, y | 23 (22–26) | 23 (22–25) | >0.99 |
| Age at time of analysis | 25 (24–28) | 27 (25–30) | 0.28 |
| Mo followed in clinic | 27 (22–34) | 54 (39–70) | 0.01 |
| Height, m | 1.68 (1.65–1.80) | 1.70 (1.65–1.75) | 0.82 |
| Weight, kg | 47.6 (39.9–60.8) | 68.3 (60.0–81.6) | 0.02 |
| BMI, kg/m2 | 17.2 (13.5–18.2) | 23.5 (19.5–29.1) | 0.01 |
| Heart rate, bpm | 106 (76–117) | 83 (74–85) | 0.08 |
| Systolic blood pressure, mm Hg | 107 (101–110) | 117 (110–127) | 0.03 |
| Diastolic blood pressure, mm Hg | 65 (64–79) | 72 (65–80) | 0.39 |
| Mean arterial blood pressure, mm Hg | 79 (71–89) | 87 (82–93) | 0.14 |
| AST, units/L | 34 (21–50) | 37 (32–42) | 0.61 |
| ALT, units/L | 30 (19–47) | 43 (36–58) | 0.06 |
| Hemoglobin, g/dL | 14.0 (12.8–15.8) | 14.4 (13.9–15.0) | 0.87 |
| Hematocrit, % | 42 (39–47) | 43 (42–45) | 0.81 |
| Platelets, ×109 cells/μL | 234 (156–255) | 263 (188–319) | 0.45 |
| CK, units/L | 537 (255–882) | 447 (307–464) | 0.26 |
| CK‐MB, units/L | 17 (7–24) | 13 (11–14) | 0.51 |
| NT‐proBNP, pg/mL | 665 (72–1632) | 46 (19–79) | 0.04 |
| FEV1% predicted | 8 (8–41) | 17 (12–53) | 0.19 |
| FVC% predicted | 7 (7–42) | 17 (14–50) | 0.09 |
| FEV1/FVC, % | 97 (94–99) | 83 (67–89) | 0.03 |
| Maximum expiratory pressure, cmH2O | 13 (0–30) | 18 (10–45) | 0.38 |
| Maximum inspiratory pressure, cmH2O | 13 (0–30) | 33 (25–35) | 0.10 |
| Ejection fraction, % | 35 (28–45) | 47 (27–52) | 0.62 |
ALT indicates alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; bpm, beats per minute; CK, creatinine kinase; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; IQR, interquartile range; MB, muscle‐brain isoenzyme; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide.